Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line
- PMID: 9523731
- DOI: 10.1007/s002800050752
Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line
Abstract
Purpose: Studies were designed to elucidate the basis for the antiproliferative activity of the anthracycline antibiotic, idarubicin (4-demethoxy-daunorubicin) in MCF-7 breast tumor cells.
Methods: Growth inhibition was evaluated using the MTT tetrazolium dye assay, induction of DNA strand breaks was determined by alkaline elution, inhibition of DNA synthesis was assessed by measuring the incorporation of labelled thymidine into DNA, modulation of the expression of the c-myc oncogene was determined by Northern blotting and the induction of apoptosis was evaluated by alkaline unwinding, static field gel electrophoresis, terminal end labelling and assessment of cell morphology.
Results: MCF-7 cells were relatively sensitive to idarubicin, with an IC50 value for growth inhibition of approximately 0.01 microM. While DNA strand breakage was not evident below a concentration of 0.1 microM idarubicin, where growth inhibition exceeded 70%, both the inhibition of DNA synthesis and suppression of c-myc expression closely paralleled the profile of antiproliferative activity for idarubicin. Finally, while exposure to idarubicin resulted in a substantial loss of viable cells within 48-72 h, there was no morphological evidence of apoptotic body formation. The absence of apoptosis in cells exposed to idarubicin was supported by studies demonstrating the absence of DNA fragmentation using gel electrophoresis, alkaline elution and in situ DNA end-labelling assays.
Conclusions: The results of these studies extend previous results from this laboratory indicating an association between suppression of c-myc expression, inhibition of DNA synthesis and growth arrest by topoisomerase II inhibitors, as well as the lack of induction of apoptotic cell death by topoisomerase II inhibitors in MCF-7 breast tumor cells.
Similar articles
-
Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression.Cancer Res. 1993 Aug 1;53(15):3547-54. Cancer Res. 1993. PMID: 8339261
-
Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.Cancer Res. 1989 Sep 1;49(17):4846-51. Cancer Res. 1989. PMID: 2758416
-
Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.Biochem Pharmacol. 1998 Apr 15;55(8):1263-9. doi: 10.1016/s0006-2952(97)00618-7. Biochem Pharmacol. 1998. PMID: 9719482
-
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.Biochem Pharmacol. 1999 Apr 1;57(7):727-41. doi: 10.1016/s0006-2952(98)00307-4. Biochem Pharmacol. 1999. PMID: 10075079 Review.
-
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010. Drugs. 1991. PMID: 1723369 Review.
Cited by
-
A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.Cells. 2022 Jul 20;11(14):2246. doi: 10.3390/cells11142246. Cells. 2022. PMID: 35883689 Free PMC article.
-
Integrating yeast chemical genomics and mammalian cell pathway analysis.Acta Pharmacol Sin. 2019 Sep;40(9):1245-1255. doi: 10.1038/s41401-019-0231-y. Epub 2019 May 28. Acta Pharmacol Sin. 2019. PMID: 31138898 Free PMC article.
-
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8. Br J Cancer. 2016. PMID: 26954716 Free PMC article.
-
Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study.Iran J Pathol. 2021 Spring;16(2):109-118. doi: 10.30699/IJP.2020.120392.2310. Epub 2020 Dec 20. Iran J Pathol. 2021. PMID: 33936221 Free PMC article.
-
Transcriptional consequences of topoisomerase inhibition.Mol Cell Biol. 2001 Dec;21(24):8437-51. doi: 10.1128/MCB.21.24.8437-8451.2001. Mol Cell Biol. 2001. PMID: 11713279 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources